INSM Key Statistics, Chart & Performance
The current stock price of INSM is 206.78 USD. In the past month the price increased by 13.14%. In the past year, price increased by 174.24%.
INSM Latest News, Press Relases and Analysis
INSM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.92B | ||
| AMGN | AMGEN INC | 15.79 | 186.00B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.68 | 117.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 76.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 928.02 | 62.53B | ||
| NTRA | NATERA INC | N/A | 32.88B | ||
| BIIB | BIOGEN INC | 10.8 | 26.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 20.71B | ||
| INCY | INCYTE CORP | 15.81 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.35 | 15.15B |
Related stock screener links
About INSM
Company Profile
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,271 full-time employees. The firm is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Company Info
INSMED INC
700 Us Highway 202/206
Bridgewater NEW JERSEY 08807 US
CEO: William H. Lewis
Employees: 1271
Phone: 19089779900
INSMED INC / INSM FAQ
What does INSM do?
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,271 full-time employees. The firm is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
What is the stock price of INSMED INC today?
The current stock price of INSM is 206.78 USD. The price increased by 0.09% in the last trading session.
Does INSMED INC pay dividends?
INSM does not pay a dividend.
What is the ChartMill technical and fundamental rating of INSM stock?
INSM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the market capitalization of INSM stock?
INSMED INC (INSM) has a market capitalization of 44.10B USD. This makes INSM a Large Cap stock.
Can you provide the ownership details for INSM stock?
You can find the ownership structure of INSMED INC (INSM) on the Ownership tab.
INSM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to INSM. When comparing the yearly performance of all stocks, INSM is one of the better performing stocks in the market, outperforming 97.44% of all stocks.
INSM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to INSM. While INSM seems to be doing ok healthwise, there are quite some concerns on its profitability.
INSM Financial Highlights
Over the last trailing twelve months INSM reported a non-GAAP Earnings per Share(EPS) of -6.19. The EPS decreased by -11.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.15% | ||
| ROE | -125.2% | ||
| Debt/Equity | 0.77 |
INSM Forecast & Estimates
26 analysts have analysed INSM and the average price target is 206.22 USD. This implies a price decrease of -0.27% is expected in the next year compared to the current price of 206.78.
For the next year, analysts expect an EPS growth of -8.3% and a revenue growth 37.89% for INSM